Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Munir T, Emmerson J, Hockaday A, Oughton JB, Howard D, Phillips D, Neilson J, Pemberton N, Paneesha S, Kennedy B, Rawstron A, Hillmen P. Munir T, et al. Among authors: pemberton n. Br J Haematol. 2022 Dec;199(5):707-719. doi: 10.1111/bjh.18427. Epub 2022 Aug 26. Br J Haematol. 2022. PMID: 36017875 Free PMC article. Clinical Trial.
COVID-19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium.
Morrissey H, Ball P, Mandal A, Nevil A, Paneesha S, Basu S, Karim F, Hossain MI, Phillips N, Khawaja J, Stone J, Murray D, Randall K, Murthy V, Kishore B, Nikolousis M, Pratt G, Neilson J, Pemberton N, Wandroo F. Morrissey H, et al. Among authors: pemberton n. Br J Haematol. 2021 Jan;192(1):e11-e14. doi: 10.1111/bjh.17136. Epub 2020 Nov 5. Br J Haematol. 2021. PMID: 33151540 Free article. No abstract available.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T. Hillmen P, et al. Among authors: pemberton n. Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4. Lancet Oncol. 2023. PMID: 37142374 Free article. Clinical Trial.
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.
Pemberton N, Compagne N, Argyrou A, Evertsson E, Gunnarsson A, Kettle JG, Orme JP, Ward RA. Pemberton N, et al. ACS Med Chem Lett. 2024 Apr 5;15(5):583-589. doi: 10.1021/acsmedchemlett.3c00425. eCollection 2024 May 9. ACS Med Chem Lett. 2024. PMID: 38746885
Prevalence of Distal Symmetrical Polyneuropathy by Diabetes Prevention Program Treatment Group, Diabetes Status, Duration of Diabetes, and Cumulative Glycemic Exposure.
Lee CG, Ciarleglio A, Edelstein SL, Crandall JP, Dabelea D, Goldberg RB, Kahn SE, Knowler WC, Ma MT, White NH, Herman WH; Diabetes Prevention Program Research Group. Lee CG, et al. Diabetes Care. 2024 May 1;47(5):810-817. doi: 10.2337/dc23-2009. Diabetes Care. 2024. PMID: 38502874 Clinical Trial.
60 results